About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Contact the Docs


  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat #8 Overall Rank


« NantKwest, Inc. v. Iancu (Fed. Cir. 2018) (en banc) | Main | FDA Issues Plan for Further Facilitating Biosimilar Development »

July 30, 2018


Hey Joseph,

Reyna's opinion assesses the printed publication bar issue correctly based upon the criteria for the "dissemination" branch. Indeed, his opinion has far better reasoning on this issue than does Lourie's in Jazz Pharma which, in my opinion, contains a dreadful and manifestly erroneous assessment of the "printed publication" bar issue there. See https://www.ipwatchdog.com/2018/07/19/jazz-pharmaceuticals-federal-circuit-really-understand-dichotomy-printed-publication-bar/id=99462/ .

The comments to this entry are closed.

June 2024

Sun Mon Tue Wed Thu Fri Sat
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29